Xeris Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Xeris Pharmaceuticals
XERS Stock  USD 4.56  0.01  0.22%   
Xeris Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Xeris Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Xeris Pharmaceuticals financial statements helps investors assess Xeris Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Xeris Pharmaceuticals' valuation are summarized below:
Gross Profit
166.2 M
Profit Margin
(0.27)
Market Capitalization
703.5 M
Enterprise Value Revenue
4.3043
Revenue
203.1 M
There are over one hundred nineteen available fundamental gauges for Xeris Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should confirm Xeris Pharmaceuticals' prevalent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 522.4 M in 2025. Enterprise Value is likely to gain to about 732.3 M in 2025

Xeris Pharmaceuticals Total Revenue

213.22 Million

Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 5.6 M, Depreciation And Amortization of 13.3 M or Interest Expense of 32 M, as well as many indicators such as Price To Sales Ratio of 2.33, Dividend Yield of 0.0 or Days Sales Outstanding of 69.01. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Xeris Pharmaceuticals Correlation against competitors.
For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

Xeris Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets220.2 M323.1 M138.9 M
Slightly volatile
Other Current Liabilities41.7 M77 M23.9 M
Slightly volatile
Total Current Liabilities50.8 M100.4 M30.1 M
Slightly volatile
Other Liabilities35.3 M33.6 M12 M
Slightly volatile
Property Plant And Equipment Net16.1 M28.2 M9.4 M
Slightly volatile
Current Deferred Revenue78.2 M74.5 M29.9 M
Slightly volatile
Accounts Payable2.2 M2.3 M3.1 M
Slightly volatile
Cash68.5 M71.6 M51.4 M
Slightly volatile
Non Current Assets Total81.8 M155.4 M47.1 M
Slightly volatile
Other Assets5.7 M5.4 M1.4 M
Slightly volatile
Cash And Short Term Investments95.9 M71.6 M67.1 M
Slightly volatile
Net Receivables42.4 M40.4 M11.7 M
Slightly volatile
Common Stock Total Equity7.2 K6.9 K3.2 K
Slightly volatile
Common Stock Shares Outstanding154.1 M146.8 M45.8 M
Slightly volatile
Liabilities And Stockholders Equity220.2 M323.1 M138.9 M
Slightly volatile
Non Current Liabilities Total158.6 M252.2 M114.6 M
Slightly volatile
Capital Surpluse448.1 M426.8 M177.1 M
Slightly volatile
Other Current Assets4.7 M7.5 M3 M
Slightly volatile
Other Stockholder Equity396.2 M642.3 M228.2 M
Slightly volatile
Total Liabilities209.4 M352.7 M144.7 M
Slightly volatile
Property Plant And Equipment Gross37.2 M35.5 M10.4 M
Slightly volatile
Preferred Stock Total Equity88.4 M112.6 M82.9 M
Slightly volatile
Total Current Assets138.4 M167.7 M91.9 M
Slightly volatile
Short Term Debt22.2 M21.2 M4.5 M
Slightly volatile
Common Stock8.6 K15 K5.3 K
Slightly volatile
Property Plant Equipment11.5 M10.9 M4.2 M
Slightly volatile
Net Working Capital87.5 M67.2 M62.4 M
Slightly volatile
Short and Long Term Debt Total170.1 M271.4 M98.3 M
Slightly volatile
Long Term Debt135.2 M217 M78.2 M
Slightly volatile
Long Term Debt Total65 M100.1 M53.7 M
Slightly volatile
Capital Stock10.5 K15 K5.8 K
Slightly volatile
Non Current Liabilities Other1.9 M2 M6.3 M
Slightly volatile
Inventory27 M48.2 M12.1 M
Slightly volatile
Deferred Long Term Liabilities3.9 M7.6 M2.6 M
Slightly volatile
Intangible Assets59.6 M98.9 M20 M
Slightly volatile
Short and Long Term Debt12.1 M13.6 M14.8 M
Slightly volatile

Xeris Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income5.6 M5.3 M1.6 M
Slightly volatile
Depreciation And Amortization13.3 M12.6 M3.8 M
Slightly volatile
Interest Expense32 M30.5 M8.8 M
Slightly volatile
Selling General Administrative90.8 M163.5 M53.6 M
Slightly volatile
Total Revenue213.2 M203.1 M52.2 M
Slightly volatile
Gross Profit174.5 M166.2 M42.2 M
Slightly volatile
Other Operating Expenses142 M236.7 M86.9 M
Slightly volatile
Research Development21.5 M25.6 M20.3 M
Slightly volatile
Cost Of Revenue38.7 M36.8 M10 M
Slightly volatile
Total Operating Expenses127.2 M199.9 M78.3 M
Slightly volatile
Reconciled Depreciation13.3 M12.6 M3.6 M
Slightly volatile

Xeris Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation19.3 M18.4 M5.8 M
Slightly volatile
Begin Period Cash Flow59.5 M71.7 M50.8 M
Slightly volatile
Depreciation13.3 M12.6 M3.6 M
Slightly volatile
Capital Expenditures1 M868 K607.1 K
Slightly volatile
End Period Cash Flow63.3 M75.7 M48.4 M
Slightly volatile
Change To Netincome15.3 M14.6 M5.6 M
Slightly volatile
Dividends Paid90.3 M169.1 M80.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.332.450223.4918
Slightly volatile
Days Sales Outstanding69.0172.642391.9073
Pretty Stable
Stock Based Compensation To Revenue0.08590.09040.3426
Slightly volatile
Capex To Depreciation0.06530.06880.7505
Very volatile
Inventory Turnover0.950.76451.0115
Slightly volatile
Days Of Inventory On Hand296477201
Slightly volatile
Payables Turnover16.8916.08383.0582
Slightly volatile
Sales General And Administrative To Revenue4.667.715.9593
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue0.120.12596.1517
Slightly volatile
Capex To Revenue0.00410.00430.0852
Very volatile
Cash Per Share0.460.48810.2856
Slightly volatile
Days Payables Outstanding21.5622.693627.2 K
Slightly volatile
Income Quality1.020.67441.0423
Slightly volatile
Intangibles To Total Assets0.440.3770.4705
Slightly volatile
Current Ratio1.591.66928.1079
Slightly volatile
Receivables Turnover5.35.02467.0355
Slightly volatile
Capex Per Share0.00560.00590.0426
Very volatile
Revenue Per Share0.741.38360.7821
Slightly volatile
Interest Debt Per Share1.512.05711.1588
Slightly volatile
Debt To Assets0.430.84020.3974
Slightly volatile
Operating Cycle337550271
Slightly volatile
Days Of Payables Outstanding21.5622.693627.2 K
Slightly volatile
Ebt Per Ebit0.941.69721.0988
Slightly volatile
Long Term Debt To Capitalization1.221.1580.5417
Slightly volatile
Total Debt To Capitalization0.61.12250.5161
Slightly volatile
Quick Ratio1.131.18967.9488
Slightly volatile
Net Income Per E B T1.080.96030.9978
Very volatile
Cash Ratio0.680.71316.8833
Slightly volatile
Days Of Inventory Outstanding296477201
Slightly volatile
Days Of Sales Outstanding69.0172.642391.9073
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.821.02350.9993
Pretty Stable
Fixed Asset Turnover7.567.19834.1213
Slightly volatile
Debt Ratio0.430.84020.3974
Slightly volatile
Price Sales Ratio2.332.450223.4918
Slightly volatile
Asset Turnover0.660.62860.1879
Slightly volatile
Gross Profit Margin0.910.81860.8963
Slightly volatile

Xeris Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap522.4 M497.6 M164.7 M
Slightly volatile

Xeris Fundamental Market Drivers

Cash And Short Term Investments71.6 M

Xeris Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Xeris Pharmaceuticals Financial Statements

Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue74.5 M78.2 M
Total Revenue203.1 M213.2 M
Cost Of Revenue36.8 M38.7 M
Stock Based Compensation To Revenue 0.09  0.09 
Sales General And Administrative To Revenue 7.71  4.66 
Research And Ddevelopement To Revenue 0.13  0.12 
Revenue Per Share 1.38  0.74 
Ebit Per Revenue(0.17)(0.17)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY